Comparison of poly (ADP-ribose) polymerase inhibitors (PARPis) as maintenance therapy for newly-diagnosed and platinum-sensitive recurrent ovarian cancer with < em > BRCA < /em > mutational status: a systematic review and network meta-analysis

CONCLUSION: All PARPis showed significant benefit, with olaparib showing greater benefit in newly diagnosed and PSR OC women.REGISTRATION: CRD42021288932.PMID:38174379 | DOI:10.1080/14737140.2023.2298832

Source: Expert Review of Anticancer Therapy - January 4, 2024 Category: Cancer & Oncology Authors: Shulin Zhou Yi Jiang Chengyan Luo Lin Yuan Source Type: research